The Medtronic Newsroom is designed to assist media in finding news and information about our company.

Medtronic, founded in a Minneapolis garage in 1949 by Earl Bakken and his brother-in-law, Palmer Hermundslie, is the world’s leading maker of medical devices.

Our Mission has not changed since Earl Bakken wrote it in 1960: To contribute to human welfare by application of biomedical engineering in the research, design, manufacture, and sale of instruments or appliances that alleviate pain, restore health and extend life.

More than 9 million lives are enhanced every year by a Medtronic product or therapy; that’s one every three seconds.

Medtronic is headquartered in Minneapolis, MN and operates in more than 140 countries. The company employs 46,000 people, including 5,800 scientists and engineers, pursuing research and innovation that has led to more than 28,000 patents.

Most Recent Press ReleasesRead More
04/18/14Endurant AAA Stent Graft from Medtronic Continues Exceptional Long-Term Performance in Observational Studies
New Clinical Data from PANDORA and ENGAGE Affirm Market-Leading Medical Device's Durable, Consistent and Proven Outcomes In Endovascular Treatment of Abdominal Aortic Aneurysms MINNEAPOLIS -- April 18, 2014 -- The Endurant AAA stent graft system from Medtronic, Inc. (NYSE: MDT) continues to demonstrate exceptional long-term performance in the endovascular treatment of abdominal aortic aneurysms, according to new clinical data presented for the first time at the 2014 Charing Cross international... 
04/11/14Medtronic to Appeal Federal District Court Ruling
MINNEAPOLIS - April 11, 2014 - The Federal District Court of Delaware today granted in part Edwards Lifesciences' motion for a preliminary injunction that prevents Medtronic, Inc. (NYSE: MDT) from selling or offering to sell its CoreValve® System in the United States. Today's ruling has no impact on the sale or marketing of CoreValve outside of the United States or the use of CoreValve in the current U.S. clinical trials. At Medtronic's request, the Federal District Court agreed to postpone the... 
04/10/14Medtronic CRT Devices Now Approved to Treat Patients with AV Block and Reduced Heart Function
Landmark BLOCK HF Trial Demonstrates Clinical Benefits of Biventricular Pacing in New Patient Population MINNEAPOLIS - April 10, 2014 - Medtronic, Inc. (NYSE: MDT) today announced that the U.S. Food and Drug Administration (FDA) approved an expanded indication for biventricular (BiV) pacing with Medtronic cardiac resynchronization therapy-pacemakers and -defibrillators (CRT-P and CRT-D). Medtronic CRT devices are now approved to treat patients with atrioventricular (AV) block and left ventricul... 
Medtronic in the News
02/18/14Innovation is Just What the Doctor Ordered - Shanghai Daily
08/20/13Medtronic Plans Expansion to Health Services, CEO Says – Bloomberg
08/11/13Medtronic Expands into Disease Management – Wall Street Journal
Receive E-mail Alerts E-mail Alert Icon
Sign up to receive e-mail alerts whenever Medtronic posts new information to the site. Just enter your e-mail address and click Submit.

Section Navigation

Contact Us

Medtronic, Inc.
main number(763) 514-4000
Public Relations
710 Medtronic Pkwy NE LC-110
Minneapolis, MN  55432

Media Contacts

Latest Tweets

Medtronic News

Latest Tweets

Omar Ishrak